A laboratory on Long Island has found a breakthrough in the fight against pancreatic cancer that can “intercept” its spread.

A lower apixaban dose is indicated in patients with an eGFR less than 30 mL/min/1.73 m2, regardless of dialysis status.

The Rybrevant-Lazcluze combo significantly reduced the risk of death by 25% versus Tagrisso in patients with newly diagnosed advanced EGFR-mutated NSCLC, according to data from the phase 3 ...